Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 227-242 , June 2011

Targeted anti-cancer therapy in the elderly

  • Wilson Gonsalves

      Affiliations

    • Department of Internal Medicine, Creighton University Medical Center, Omaha, NE, United States
    • ,
  • Apar Kishor Ganti

      Affiliations

    • Section of Oncology-Hematology, Department of Internal Medicine, VA Medical Center, Omaha, NE, United States
    • Section of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, United States
    • Corresponding Author InformationCorresponding author at: Department of Internal Medicine, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, United States. Tel.: +1 402 559 6210; fax: +1 402 559 6520.

,Accepted 8 June 2010.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005;11:449–460
  3. Oshita F, Kurata T, Kasai T, et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res. 1995;86:1198–1202
  4. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol. 1993;20:43–49
  5. Hardy SE, Studenski SA. Fatigue and function over 3 years among older adults. J Gerontol A: Biol Sci Med Sci. 2008;63:1389–1392
  6. Luciani A, Jacobsen PB, Extermann M, et al. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol. 2008;31:424–430
  7. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003;94:15–21
  8. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009;373:1033–1040
  9. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39
  10. Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol. 2003;30:34–46
  11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  12. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:2350–2357
  13. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760–766
  14. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144
  15. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17
  16. Carlson J, Oestreicher N, Lubeck DP, Ramsey SD, Veenstra DL. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;25:7664;[Meeting Abstracts]
  17. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966
  18. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?. J Clin Oncol. 2007;25:4506–4507[author reply 4508]
  19. Radulovic S, Bjelogrlic SK. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON. 2007;12(Suppl. 1):S151–S162
  20. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  21. Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100:1454–1463
  22. Bukowski RM, Stadler WM, Figlin RA, et al. Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America: safety and efficacy of sorafenib in elderly patients (pts) >=65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J Clin Oncol. 2008;26:5045;[Meeting Abstracts]
  23. Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol. 2006;24:4604;[Meeting Abstracts]
  24. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390
  25. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34
  26. Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost–benefit analysis while awaiting data on sorafenib safety. Hepatology. 2010;51:165–173
  27. Heng DY, Bukowski RM. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets. 2008;8:676–682
  28. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  29. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26:5024;[Meeting Abstracts]
  30. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol. 2007;25:5010;[Meeting Abstracts]
  31. Remak E, Mullins CD, Akobundu E, Charbonneau C, Woodruff K. Economic evaluations of sunitinib versus interferon-alfa (IFN-{alpha}) in first-line metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2007;25:6607;[Meeting Abstracts]
  32. Paz-Ares L, Garcia del Muro X, Grande E, Gonzalez P, Brosa M, Diaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol. 2008;10:831–839
  33. Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M. Lapatinib in metastatic breast cancer. Womens Health (Lond Engl). 2009;5:603–612
  34. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  35. Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. 2009;115:489–498
  36. Rousselot P, Nicolini F, Mahon FX, et al. High efficacy and particular safety profile of imatinib mesylate (Glivec(R)) in elderly patients with CML in chronic phase: results of the AFR04 prospective study. In: ASH Annual Meeting Abstracts, vol. 110. 2007;p. 1039
  37. Ata RL, Breccia M, Sica S, et al. Treatment with imatinib in very elderly (>75 years) CML patients. In: ASH Annual Meeting Abstracts, vol. 112. 2008;p. 1096
  38. Bassi S, Castagnetti F, Amabile M, et al. Imatinib in the treatment of CML patients >=65 years old in late chronic phase: results of a phase II study of the GIMEMA CML working party. In: ASH Annual Meeting Abstracts, vol. 104. 2004;p. 2935
  39. Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics. 2008;26:435–446
  40. Mabasa VH, Taylor SC, Chu CC, et al. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). J Oncol Pharm Pract. 2008;14:105–112
  41. Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs. 2008;22:59–69
  42. Iuliano F, Russo A, Caroleo MC, Conforti F, Serra A. Escalated dasatinib dose up to 60mg O.D. in elderly patients with chronic myeloid leukemia in late chronic phase resistant to or intolerant of imatinib-12 months follow-up. In: ASH Annual Meeting Abstracts, vol. 112. 2008;p. 4283
  43. Minda K, Taylor MJ, Cerri KH, Davis C, Kan HJ, Ray S. An economic evaluation of dasatinib as a treatment for chronic phase chronic myeloid leukaemia in Scotland. Value Health. 2007;10:14887
  44. Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer Res. 2007;13:s4613–s4616
  45. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  46. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–65
  47. Grusenmeyer PA, Gralla RJ. Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer. J Clin Oncol. 2006;24:6057;[Meeting Abstracts]
  48. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  49. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–3705
  50. Kozloff MF, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. J Clin Oncol. 2008;26:4026;[Meeting Abstracts]
  51. Raman AK, Lombardo JC, Chandrasekhar R, Fakih MG. Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer. J Clin Oncol. 2007;25:14546;[Meeting Abstracts]
  52. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11:1–128iii–iv
  53. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  54. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45:1397–1406
  55. Bajetta E, Ravaud A, Bracarda S, et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-{alpha}2a (IFN) in patients (pts) >=65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26:5095;[Meeting Abstracts]
  56. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72:1217–1222
  57. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239
  58. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther. 2005;27:684–694
  59. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  60. Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer. J Clin Oncol. 2007;25:14528;[Meeting Abstracts]
  61. Sastre J, Aranda E, Gravalos C, et al. Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer. Preliminary results of a TTD phase II study. Ann Oncol. 2006;17(Suppl. 9):ix114
  62. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995
  63. Rivera F, Gravalos C, Massutí B, et al. 4004 cetuximab plus capecitabine as first-line treatment for elderly patients (pts) with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status—the TTD-06-01 Spanish Cooperative Group trial. Eur J Cancer Suppl. 2009;7:216–1216
  64. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst. 2009;101:1182–1192
  65. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127
  66. Sambrook J, Levy AR, Johnston KM, et al. Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada. J Clin Oncol. 2009;27:e17000;[Meeting Abstracts]
  67. Van Cutsem E, Peeters M, Siena S, et al. A phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. In: Proc Gastrointestinal Cancers Symposium. 2007;p. 349
  68. Peeters M, Price T, Hotko Y, et al. 14LBA randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Eur J Cancer Suppl. 2009;7:10
  69. Douillard J, Siena S, Cassidy J, et al. 10LBA randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer Suppl. 2009;7:6–16
  70. Graham CN, Borker R, Oppe M, et al. Cost-effectiveness of panitumumab plus best supportive care (BSC) compared with BSC alone in chemorefractory metastatic colorectal cancer patients with wild-type KRAS tumor status in Netherlands. Ann Oncol. 2009;19:134
  71. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18:977–984
  72. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  73. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  74. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  75. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819
  76. Giuliani R, Minisini AM, Paesmans M, et al. Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (H)? Results from two Belgian compassionate use programs in metastatic breast cancer (MBC) patients (pts). J Clin Oncol. 2004;22:838;[Meeting Abstracts]
  77. Brunello A, Monfardini S, Crivellari D, et al. Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (>=70 years). J Clin Oncol. 2008;26:1096;[Meeting Abstracts]
  78. Fyfe GA, Mass R, Murphy M, Slamon DJ. Survival benefit of traztuzumab (herceptin) and chemotherapy in older (age>60) patients. Proc Am Soc Clin Oncol. 2001;20:[Abstr. 189]
  79. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25:625–633
  80. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40:3147–3154
  81. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126
  82. Habermann TM, Weller EA, Morrison VA, et al. Rituximab–CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127
  83. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol. 2005;74:194–202
  84. Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007;22:684–691
  85. Thompson S, van Agthoven M. Cost-effectiveness of 90Y-ibritumomab tiuxetan (90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma. In: ASH Annual Meeting Abstracts, vol. 106. 2005;p. 2436
  86. Gregory SA, Zelenetz A, Knox SJ, Vose J, Leonard JP, Kaminski M. Tositumomab and iodine I 131 tositumomab (the BEXXAR(R) therapeutic regimen) shows efficacy in elderly patients (pts) with relapsed/refractory low-grade (LG), follicular, and transformed non-Hodgkin's lymphoma (NHL). In: ASH Annual Meeting Abstracts, vol. 104. 2004;p. 2630
  87. Flowers CR, Sambrook JC, Briggs A, Osenenko K, Wang H, Dalal MR. Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL). J Clin Oncol. 2007;25:8089;[Meeting Abstracts]
  88. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165–2172
  89. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429–435
  90. Bagust A, Haycox AR, Boland A, et al. Economic evaluation of bortezomib (VELCADE) for relapsed and refractory multiple myeloma. In: ASH Annual Meeting Abstracts, vol. 104. 2004;p. 268
  91. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13:5291–5294
  92. Ludwig H, Hajek R, Tothova E, et al. Thalidomide–dexamethasone compared with melphalan–prednisolone in elderly patients with multiple myeloma. Blood. 2009;113:3435–3442
  93. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436
  94. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–831
  95. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–1218
  96. List AF. Lenalidomide: from bench to bedside (part 1). Cancer Control. 2006;13(Suppl.):2–3
  97. Reece DE, Masih-Khan E, Chen C, et al. Lenalidomide (Revlimid(R)) +/− corticosteroids in elderly patients with relapsed/refractory multiple myeloma. In: ASH Annual Meeting Abstracts, vol. 108. 2006;p. 3550
  98. Chanan-Khan A, Dimopoulos MA, Weber DM, et al. Safety and efficacy outcomes with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma were not significantly different for the treatment of patients with or without high-risk disease or elderly status. In: ASH Annual Meeting Abstracts, vol. 112. 2008;p. 3701
  99. Ritchie E, Lachs M. Management of myelodysplastic syndromes in the geriatric patient. Curr Hematol Malign Rep. 2009;4:3–9
  100. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465

PII: S1040-8428(10)00141-1

doi: 10.1016/j.critrevonc.2010.06.001

Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 227-242 , June 2011

Article Tools